Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
A comprehensive evidence map of 73 AI studies across radiopharmaceutical therapy finds impressive technical progress in ...
Radionuclide therapy delivered directly to an artery is safe and feasible for patients with advanced meningioma, according to new research published in the December issue of The Journal of Nuclear ...
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...
The role of Ki-67 in determining optimal chemotherapy in high grade neuroendocrine tumors. Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high ...
A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) No significant financial relationships to disclose. This is ...
A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this ...
The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Of patients with ...
Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine ...
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results